Teva Recalls Drug Vials, Shuts Facility Over Mold Concerns - TheStreet
Celltrion slammed with US FDA warning at biosimilar site
書籍紹介］ FDAのGMP査察から学ぶ 第２版 読めばわかる 査察官の視点・指摘の意図 | PHARM TECH JAPAN ONLINE-製剤技術とGMPの最先端技術情報サイト
Teva catches break as warning letter looks to delay Momenta Copaxone generic | FiercePharma
Aurobindo Receives Warning Letter After Form 483 :: Generics Bulletin
Teva receives warning letter over Actavis site
Teva receives warning letter over Actavis site
Teva plant tagged with warning letter for issues making schizophrenia drug | FiercePharma
Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International
angiotensin II receptor blockers (ARBs) - News, Articles etc. - European Pharmaceutical Review
FDA Bans Imports From Teva's Hungary Plant Except Two Drugs in Shortage | RAPS
Teva Reports Second Quarter 2020 Financial Results | Business Wire
Sanofi begins work on succession plan; FDA issues warning letters to Lupin's US, India units | Radio Compass Blog
UPDATED: Teva's struggling sterile plant hit with FDA warning letter | FiercePharma
Celltrion receives FDA 483 with 8 'manageable and correctible' observations - BioProcess InternationalBioProcess International
/cloudfront-us-east-2.images.arcpublishing.com/reuters/CCBS56SBRRKUDM7JEVVE3UOQEE.jpg "Teva halts output at U.S. drug plant after FDA flags concerns | Reuters")
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva Stops Production At US Plant After FDA Concerns: Report
FDA Regulation of Promotion & Advertising -- Part 4: FDA Enforcement…
Teva settles with Roche to launch first Rituxan biosimilar in US - BioProcess InternationalBioProcess International
Food & Drug Administration (FDA) Archives - Page 231 of 509 - MassDevice
FDA cites 'significant' sterility concern at Teva injectables plant | FiercePharma
Teva partners with Just Biotherapeutics, ramping up biologics productivity - BioProcess InsiderBioProcess International
Analysis of FDA Infrared 483 Citations: Have You a Data Integrity Problem?
FDA Form 483 shows Pfizer repeating same mistakes at troubled fill-finish plant | FiercePharma
Biosimilar… but different: FDA tweaking nonproprietary name guidance - BioProcess InternationalBioProcess International
Generic Drug Giant Recalls Millions of Drugs Over Mold Concerns • Drugwatcher.org
Teva's struggling sterile plant hit with FDA warning letter - Skyland Analytics
FDA Keeps Brand-Name Drugs On A Fast Path To Market ― Despite Manufacturing Concerns | Kaiser Health News
